From FDA labels and ClinicalTrials.gov

Do GLP-1s reduce inflammation?

Last updated

If your prescriber prescribes one: the lowest self-pay GLP-1 prices now

  • Lowest compounded tirzepatide on a monthly plan, not FDA-approved

    Collective

    $69/mo + $199/yr membership · about $86 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

  • Lowest compounded semaglutide on a monthly plan, not FDA-approved

    Collective

    $59/mo + $199/yr membership · about $76 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

  • Lowest FDA-approved, starting dose

    LillyDirect (Eli Lilly)

    from $149/mo

  • Lowest FDA-approved injection, starting dose

    NovoCare (Novo Nordisk)

    $199/fill initially

No current GLP-1 label lists inflammation as an approved use, so prescribing one for it would be off-label. STEP 1, 2 and 3 (Semaglutide 2.4 mg): C-reactive protein, a blood marker of inflammation, fell 44%, 39% and 48% more than on placebo in the three trials at 68 weeks, in parallel with weight loss. This is a marker in the blood: it does not show that a person feels or fares better. EClinicalMedicine, 2022 (pubmed.ncbi.nlm.nih.gov/36467859). ClinicalTrials.gov lists 23 trials of these medicines on it: 2 with posted results and 4 recruiting now.

Read from the registry and PubMed every day. The newest update here is Nov 18, 2026.

Published results

What the largest trials on inflammation found

Each read in the paper's abstract on Nov 6, 2026. Trials differ in who took part and how long they ran.

STEP 1, 2 and 3

Semaglutide 2.4 mg · Mixed · Placebo-controlled randomized trial

C-reactive protein, a blood marker of inflammation, fell 44%, 39% and 48% more than on placebo in the three trials at 68 weeks, in parallel with weight loss. This is a marker in the blood: it does not show that a person feels or fares better.

EClinicalMedicine, 2022 (pubmed.ncbi.nlm.nih.gov/36467859)

41 randomized trials, pooled

GLP-1s and tirzepatide · Mixed · Meta-analysis

In type 2 diabetes, GLP-1s lowered C-reactive protein across 27 studies. Their effects on two other inflammation markers, IL-6 and TNF-alpha, were not statistically significant. Two tirzepatide trials showed a significant fall in IL-6 and a non-significant trend towards lower C-reactive protein.

Diabetes Obes Metab, 2026 (pubmed.ncbi.nlm.nih.gov/42449480)

The registry

Trials on inflammation, by medicine

A trial counts when the registry's conditions or title name this, and some study a related question, such as insulin sensitivity in people with the condition. A registered trial shows a question being asked, not that the answer is yes.

MedicineTrialsPosted resultsRecruiting
Semaglutide802
Liraglutide710
Exenatide410
Tirzepatide402
Posted results

What trials on inflammation reported

Latest phases and largest trials first. Each result is the first primary outcome as its sponsor posted it to the registry, which is not peer review.

TrialMedicinePhasePeopleResult
NCT03260881Liraglutide Effects on Epicardial Fat Inflammatory GenesLiraglutidePhase 438On ClinicalTrials.gov (clinicaltrials.gov)
NCT01951651Effect of Exenatide on Liver and Heart Fat and InflammationExenatidePhase 424Myocardial Fat Content (percentage of myocardium content), 6 months. Exenatide: 1.7; Glipizide: 1.1.
Recruiting now

Trials on inflammation taking people now

The registry page names each site and who can enroll. Ask your clinician before joining one.

TrialMedicinePhaseExpected to finish
GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM (clinicaltrials.gov/study/NCT07314684)SemaglutidePhase 4Mar 8, 2027
Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis (clinicaltrials.gov/study/NCT07401992)SemaglutidePhase 4Feb 28, 2027
Tirzepatide for Ileal Pouch-anal Anastomosis (IPAA) and Chronic High Bowel Frequency (I8F-NS-X008) (clinicaltrials.gov/study/NCT07756359)TirzepatidePhase 4Sep 2027
Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease (clinicaltrials.gov/study/NCT06976853)TirzepatidePhase 2Aug 2028
From PubMed

Newest papers on GLP-1s and inflammation

  • Effects of exercise and liraglutide on vascular health and inflammation during weight loss maintenance: a prespecified secondary analysis of the S-LiTE trial (pubmed.ncbi.nlm.nih.gov/42342869)

    Randomized trial · Nat Metab · Jun 24, 2026 · Sandsdal RM et al. · cited by 2

  • GLP-1 and its derivatives are associated with the reduction of macrophage infiltration and inflammation in systemic chronic inflammatory diseases: a systematic review and meta-analysis of animal models (pubmed.ncbi.nlm.nih.gov/41843040)

    Meta-analysis · Immunol Res · Mar 17, 2026 · Sha H et al. · cited by 1

  • Acute interleukin-1β antagonism decreases systemic inflammation, increases GLP-1 release, and modulates insulin secretion in individuals with prediabetes (pubmed.ncbi.nlm.nih.gov/41778408)

    Randomized trial · Am J Physiol Endocrinol Metab · Mar 4, 2026 · Fischer JS et al. · cited by 2

  • Effect of once-weekly subcutaneous semaglutide on arterial inflammation in people with type 2 diabetes and cardiovascular disease using PET-MRI: Primary results of a randomized, double-blind, placebo-controlled trial (pubmed.ncbi.nlm.nih.gov/40345413)

    Randomized trial · Am Heart J · May 7, 2025 · James S et al. · cited by 5

Listed from Europe PMC as published, newest first. A listing here is not a judgement of a study's quality or a recommendation.

Updated automatically

What changed in trials on inflammation

  • TrialTirzepatide study now recruiting (was not yet recruiting): Tirzepatide for Ileal Pouch-anal Anastomosis (IPAA) and Chronic High Bowel Frequency (I8F-NS-X008) (clinicaltrials.gov/study/NCT07756359)
  • TrialTirzepatide study now active, not recruiting (was recruiting): Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients (clinicaltrials.gov/study/NCT06774079)

Written from each source's own record as it changes. Every change on GLPcompare

Questions

GLP-1s and inflammation: common questions

What did the largest trial on inflammation find?

STEP 1, 2 and 3 (Semaglutide 2.4 mg): C-reactive protein, a blood marker of inflammation, fell 44%, 39% and 48% more than on placebo in the three trials at 68 weeks, in parallel with weight loss. This is a marker in the blood: it does not show that a person feels or fares better.

Is any GLP-1 FDA approved for inflammation?

Not in any current label we read. A prescriber can still use a medicine off-label, but insurance often limits coverage to approved uses, so ask your plan.

Which GLP-1 has been studied most for inflammation?

Semaglutide, with 8 registered trials on it, then Liraglutide with 7. More trials do not mean better results: read what each posted.

Can I join a trial of a GLP-1 for inflammation?

4 trials are recruiting on ClinicalTrials.gov now, listed on this page with their registry pages, which name each site and who can enroll.

Other conditions

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.